Latest Articles

Publication Date
Endometrial Cancer Market: Opportunities, Challenges, - openPR

Endometrial Cancer Market: Opportunities, Challenges, openPR

Published: Dec. 10, 2024, 7:16 a.m.
GSK Korea expands indication for Jemperli in endometrial cancer treatment - KBR

GSK Korea expands indication for Jemperli in endometrial cancer treatment KBR

Published: Dec. 10, 2024, 3:13 a.m.
Top Gynecologic Cancer Research of 2024 - Cancer Therapy Advisor

Top Gynecologic Cancer Research of 2024 Cancer Therapy Advisor

Published: Dec. 9, 2024, 3 p.m.
The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer - Targeted Oncology

The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer Targeted Oncology

Published: Dec. 8, 2024, 5 p.m.
Balancing VTE and bleeding risks in gynecologic cancer surgeries - Contemporary Obgyn

Balancing VTE and bleeding risks in gynecologic cancer surgeries Contemporary Obgyn

Published: Dec. 6, 2024, 8:37 p.m.
Florida Cancer Specialists & Research Institute Case Study Demonstrates Value of Genomic Testing To Improve Treatment and Outcomes For Patients With Inherited Cancers - The Malaysian Reserve

Florida Cancer Specialists & Research Institute Case Study Demonstrates Value of Genomic Testing To Improve Treatment and Outcomes For Patients With Inherited Cancers The Malaysian Reserve

Published: Dec. 6, 2024, 4:44 p.m.
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - BioSpace

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer BioSpace

Published: Dec. 6, 2024, 8:22 a.m.
Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer - OncLive

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer OncLive

Published: Dec. 5, 2024, 7:04 p.m.
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - The Malaysian Reserve

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer The Malaysian Reserve

Published: Dec. 5, 2024, 3:36 p.m.
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - Canada NewsWire

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer Canada NewsWire

Published: Dec. 5, 2024, 2:43 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!